| pubmed-article:18301896 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18301896 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:18301896 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:18301896 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:18301896 | lifeskim:mentions | umls-concept:C0439230 | lld:lifeskim |
| pubmed-article:18301896 | lifeskim:mentions | umls-concept:C1436671 | lld:lifeskim |
| pubmed-article:18301896 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18301896 | pubmed:dateCreated | 2008-8-15 | lld:pubmed |
| pubmed-article:18301896 | pubmed:abstractText | Cantuzumab mertansine (SB-408075; huC242-DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen. In previous studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses. Based on those studies, it was suggested that treatment at intervals of the half-life of the intact immunoconjugate may allow a higher dose density. This provided the rationale for the three-times weekly treatment explored in this protocol. | lld:pubmed |
| pubmed-article:18301896 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18301896 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301896 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18301896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301896 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18301896 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:18301896 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:LambertJohn... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:HammondLisa... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:HaoDesiréeD | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:TolcherAnthon... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:XieHongshengH | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:TakimotoChris... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:SmithLonL | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:PanditeLiniL | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:HowardMariaM | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:GarrisonMitch... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:ForeroLeonard... | lld:pubmed |
| pubmed-article:18301896 | pubmed:author | pubmed-author:RodonJordiJ | lld:pubmed |
| pubmed-article:18301896 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18301896 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:18301896 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18301896 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18301896 | pubmed:pagination | 911-9 | lld:pubmed |
| pubmed-article:18301896 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:meshHeading | pubmed-meshheading:18301896... | lld:pubmed |
| pubmed-article:18301896 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18301896 | pubmed:articleTitle | Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. | lld:pubmed |
| pubmed-article:18301896 | pubmed:affiliation | Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite #414, San Antonio, TX 78229, USA. jrodon@idd.org | lld:pubmed |
| pubmed-article:18301896 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18301896 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
